Back

Effectiveness and safety of mavacamten in obstructive hypertrophic cardiomyopathy in the real world: one-year data from the multicentre MARVEL.HU study

10 May 2026 (12:30 - 13:30)
Organised by: Logo
Congress Presentation Part of: ePosters in myocardial disease - hypertrophic cardiomyopathy (2) Hypertrophic Cardiomyopathy Delegates Premium Access Heart Failure 2026 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Robert Sepp

University of Szeged, Szeged (Hungary)

8 More presentations in this session

Presentation thumbnail
Impact of hypertrophic cardiomyopathy on work productivity and activity impairment in patients with HCM: analysis of a real-world cross-sectional survey
Doctor P. Gebrehiwet (South San Francisco, US)
Abstract Slides
Presentation thumbnail
Hypertrophic cardiomyopathy and fabry disease: right ventricular to pulmonary artery coupling can differentiate both?
Doctor A. Castro Pinto (Guimaraes, PT)
Abstract Slides
Presentation thumbnail
Validating prediction models for hypertrophic cardiomyopathy genotype positivity
Mr P. Kopp (Stony Brook, US)
Abstract Slides
Presentation thumbnail
ICD benefit in hypertrophic cardiomyopathy: a real-world analysis
Doctor D. Ferreira (Lisbon, PT)
Abstract Slides
Presentation thumbnail
Heart failure profile in hypertrophic cardiomyopathy
Doctor N. Przytula (Krakow, PL)
Abstract Slides

Access the full session

Session thumbnail
ePosters in myocardial disease - hypertrophic cardiomyopathy (2)

The Event

Event poster

Heart Failure 2026

10 May 2026 12:30 CET

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources